Visus TherapeuticsVisus Therapeutics announced today that it entered into worldwide licensing agreements with Cella Therapeutics and DelSiTech.

The exclusive worldwide licensing agreement with Cella covers the development of investigational ophthalmic therapies for treating glaucoma and age-related macular degeneration (AMD). The additional worldwide exclusive licensing agreement with DelSiTech will lead to the development of novel drug delivery technology to help optimize the clinical benefit of ophthalmic therapies.

Get the full story at our sister site, Drug Delivery Business News.